Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort
Aims/hypothesis Tenascin-C (TN-C) is an extracellular matrix glycoprotein highly expressed in inflammatory and cardiovascular (CV) diseases. Serum TN-C has not yet been specifically studied in individuals with type 2 diabetes, a condition associated with chronic low-grade inflammation and increased CV disease risk. In this study, we hypothesised that elevated serum TN-C at enrolment in participants with type 2 diabetes would be associated with increased risk of death and major adverse CV events (MACE) during follow-up. Methods We used a prospective, monocentric cohort of consecutive type 2 diabetes participants (the SURDIAGENE [SUivi Rénal, DIAbète de type 2 et GENEtique] cohort) with all-cause death as a primary endpoint and MACE (CV death, non-fatal myocardial infarction or stroke) as a secondary endpoint. We used a proportional hazard model after adjustment for traditional risk factors and the relative integrated discrimination improvement (rIDI) to assess the incremental predictive value of TN-C for these risk factors. Results We monitored 1321 individuals (58% men, mean age 64 ± 11 years) for a median of 89 months. During follow-up, 442 individuals died and 497 had MACE. Multivariate Cox analysis showed that serum TN-C concentrations were associated with an increased risk of death (HR per 1 SD: 1.27 [95% CI 1.17, 1.38]; p < 0.0001) and MACE (HR per 1 SD: 1.23 [95% CI 1.13, 1.34]; p < 0.0001). Using TN-C concentrations on top of traditional risk factors, prediction of the risk of all-cause death (rIDI: 8.2%; p = 0.0006) and MACE (rIDI: 6.7%; p = 0.0014) improved significantly, but modestly. Conclusions/interpretation In individuals with type 2 diabetes, increased serum TN-C concentrations were independently associated with death and MACE. Therefore, including TN-C as a prognostic biomarker could improve risk stratification in these individuals..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
---|---|
Enthalten in: |
Diabetologia - 63(2020), 5 vom: 10. Feb., Seite 915-923 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gellen, Barnabas [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
doi: |
10.1007/s00125-020-05108-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR039360903 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR039360903 | ||
003 | DE-627 | ||
005 | 20230519192852.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00125-020-05108-5 |2 doi | |
035 | |a (DE-627)SPR039360903 | ||
035 | |a (DE-599)SPRs00125-020-05108-5-e | ||
035 | |a (SPR)s00125-020-05108-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.89 |2 bkl | ||
100 | 1 | |a Gellen, Barnabas |e verfasserin |4 aut | |
245 | 1 | 0 | |a Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Aims/hypothesis Tenascin-C (TN-C) is an extracellular matrix glycoprotein highly expressed in inflammatory and cardiovascular (CV) diseases. Serum TN-C has not yet been specifically studied in individuals with type 2 diabetes, a condition associated with chronic low-grade inflammation and increased CV disease risk. In this study, we hypothesised that elevated serum TN-C at enrolment in participants with type 2 diabetes would be associated with increased risk of death and major adverse CV events (MACE) during follow-up. Methods We used a prospective, monocentric cohort of consecutive type 2 diabetes participants (the SURDIAGENE [SUivi Rénal, DIAbète de type 2 et GENEtique] cohort) with all-cause death as a primary endpoint and MACE (CV death, non-fatal myocardial infarction or stroke) as a secondary endpoint. We used a proportional hazard model after adjustment for traditional risk factors and the relative integrated discrimination improvement (rIDI) to assess the incremental predictive value of TN-C for these risk factors. Results We monitored 1321 individuals (58% men, mean age 64 ± 11 years) for a median of 89 months. During follow-up, 442 individuals died and 497 had MACE. Multivariate Cox analysis showed that serum TN-C concentrations were associated with an increased risk of death (HR per 1 SD: 1.27 [95% CI 1.17, 1.38]; p < 0.0001) and MACE (HR per 1 SD: 1.23 [95% CI 1.13, 1.34]; p < 0.0001). Using TN-C concentrations on top of traditional risk factors, prediction of the risk of all-cause death (rIDI: 8.2%; p = 0.0006) and MACE (rIDI: 6.7%; p = 0.0014) improved significantly, but modestly. Conclusions/interpretation In individuals with type 2 diabetes, increased serum TN-C concentrations were independently associated with death and MACE. Therefore, including TN-C as a prognostic biomarker could improve risk stratification in these individuals. | ||
650 | 4 | |a Cardiovascular risk |7 (dpeaa)DE-He213 | |
650 | 4 | |a MACE |7 (dpeaa)DE-He213 | |
650 | 4 | |a Tenascin-C |7 (dpeaa)DE-He213 | |
650 | 4 | |a Type 2 diabetes |7 (dpeaa)DE-He213 | |
700 | 1 | |a Thorin-Trescases, Nathalie |e verfasserin |4 aut | |
700 | 1 | |a Thorin, Eric |e verfasserin |4 aut | |
700 | 1 | |a Gand, Elise |e verfasserin |4 aut | |
700 | 1 | |a Sosner, Philippe |e verfasserin |4 aut | |
700 | 1 | |a Brishoual, Sonia |e verfasserin |4 aut | |
700 | 1 | |a Rigalleau, Vincent |e verfasserin |4 aut | |
700 | 1 | |a Montaigne, David |e verfasserin |4 aut | |
700 | 1 | |a Javaugue, Vincent |e verfasserin |4 aut | |
700 | 1 | |a Pucheu, Yann |e verfasserin |4 aut | |
700 | 1 | |a Gatault, Philippe |e verfasserin |4 aut | |
700 | 1 | |a Piguel, Xavier |e verfasserin |4 aut | |
700 | 1 | |a Hadjadj, Samy |e verfasserin |4 aut | |
700 | 1 | |a Saulnier, Pierre-Jean |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetologia |d Berlin : Springer, 1965 |g 63(2020), 5 vom: 10. Feb., Seite 915-923 |w (DE-627)SPR000960098 |w (DE-600)1458993-X |x 1432-0428 |7 nnns |
773 | 1 | 8 | |g volume:63 |g year:2020 |g number:5 |g day:10 |g month:02 |g pages:915-923 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00125-020-05108-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.89 |q ASE |
951 | |a AR | ||
952 | |d 63 |j 2020 |e 5 |b 10 |c 02 |h 915-923 |